Healthcare | June 20, 2026
Quadria-backed HealthQuad closes Rs. 550 crore first close for fund 3
Backs Lifesigns in first bet and doubles down on India’s healthcare AI surge
Backs Lifesigns in first bet and doubles down on India’s healthcare AI surge
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
CEO Stéphane Bancel framed the changes as essential to scaling the business
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
